{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T18:30:05Z","timestamp":1787941805191,"version":"build-2784847793"},"reference-count":29,"publisher":"American Society for Microbiology","issue":"12","license":[{"start":{"date-parts":[[2012,12,1]],"date-time":"2012-12-01T00:00:00Z","timestamp":1354320000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2012,12]]},"abstract":"ABSTRACT<\/jats:title>\n \n More than 5 million Americans are bitten by animals, usually dogs, annually. Bite patients comprise \u223c1% of all patients who visit emergency departments (300,000\/year), and approximately 10,000 require hospitalization and intravenous antibiotics. Ceftaroline is the bioactive component of the prodrug ceftaroline fosamil, which is FDA approved for the treatment of acute bacterial skin and skin structure infections (ABSSSIs), including those containing methicillin-resistant\n Staphylococcus aureus<\/jats:named-content>\n (MRSA). There are no\n in vitro<\/jats:italic>\n data about the activity of ceftaroline against\n Pasteurella multocida<\/jats:named-content>\n subsp.\n multocida<\/jats:named-content>\n and\n Pasteurella multocida<\/jats:named-content>\n subsp.\n septica<\/jats:named-content>\n , other\n Pasteurella<\/jats:named-content>\n spp., or other bite wound isolates. We therefore studied the\n in vitro<\/jats:italic>\n activity of ceftaroline against 243 animal bite isolates. MICs were determined using the broth microdilution method according to CLSI guidelines. Comparator drugs included cefazolin, ceftriaxone, ertapenem, ampicillin-sulbactam, azithromycin, doxycycline, and sulfamethoxazole-trimethoprim (SMX-TMP). Ceftaroline was the most active agent against all 5\n Pasteurella<\/jats:named-content>\n species, including\n P. multocida<\/jats:named-content>\n subsp.\n multocida<\/jats:named-content>\n and\n P. multocida<\/jats:named-content>\n subsp.\n septica<\/jats:named-content>\n , with a maximum MIC of \u22640.008 \u03bcg\/ml; more active than ceftriaxone and ertapenem (MIC\n 90<\/jats:sub>\n s, \u22640.015 \u03bcg\/ml); and more active than cefazolin (MIC\n 90<\/jats:sub>\n , 0.5 \u03bcg\/ml) doxycycline (MIC\n 90<\/jats:sub>\n , 0.125 \u03bcg\/ml), azithromycin (MIC\n 90<\/jats:sub>\n , 0.5 \u03bcg\/ml), ampicillin-sulbactam (MIC\n 90<\/jats:sub>\n , 0.125 \u03bcg\/ml), and SMX-TMP (MIC\n 90<\/jats:sub>\n , 0.125 \u03bcg\/ml). Ceftaroline was also very active against all\n S. aureus<\/jats:named-content>\n isolates (MIC\n 90<\/jats:sub>\n , 0.125 \u03bcg\/ml) and other\n Staphylococcus<\/jats:named-content>\n and\n Streptococcus<\/jats:named-content>\n species, with a maximum MIC of 0.125 \u03bcg\/ml against all bite isolates tested. Ceftaroline has potential clinical utility against infections involving\n P. multocida<\/jats:named-content>\n , other\n Pasteurella<\/jats:named-content>\n species, and aerobic Gram-positive isolates, including\n S. aureus<\/jats:named-content>\n .\n <\/jats:p>","DOI":"10.1128\/aac.01794-12","type":"journal-article","created":{"date-parts":[[2012,10,2]],"date-time":"2012-10-02T06:20:19Z","timestamp":1349158819000},"page":"6319-6323","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":24,"title":["Ceftaroline versus Isolates from Animal Bite Wounds: Comparative\n In Vitro<\/i>\n Activities against 243 Isolates, Including 156 Pasteurella Species Isolates"],"prefix":"10.1128","volume":"56","author":[{"given":"Ellie J. C.","family":"Goldstein","sequence":"first","affiliation":[{"name":"R. M. Alden Research Laboratory, Culver City, California, USA"},{"name":"David Geffen School of Medicine at UCLA, Los Angeles, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diane M.","family":"Citron","sequence":"additional","affiliation":[{"name":"R. M. Alden Research Laboratory, Culver City, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. Vreni","family":"Merriam","sequence":"additional","affiliation":[{"name":"R. M. Alden Research Laboratory, Culver City, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerin L.","family":"Tyrrell","sequence":"additional","affiliation":[{"name":"R. M. Alden Research Laboratory, Culver City, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1111\/j.1865-1682.2011.01273.x","article-title":"Methicillin-resistant Staphylococcus aureus: an emerging pathogen of pets in Egypt with a public health burden","volume":"59","author":"Abdel-Moein KA","year":"2012","unstructured":"Abdel-MoeinKA El-HairiM SamirA. 2012. Methicillin-resistant Staphylococcus aureus: an emerging pathogen of pets in Egypt with a public health burden. Transbound. Emerg. Dis. 59:331\u2013335.","journal-title":"Transbound. Emerg. Dis."},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00041-10"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-3164.2012.01046.x"},{"key":"e_1_3_2_5_2","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1093\/cid\/cir714","article-title":"Methicillin-resistant Staphylococcus aureus (MRSA) isolated from pets living in households with MRSA-infected children","volume":"54","author":"Bender JB","year":"2012","unstructured":"BenderJB WatersKC NerbyJ OlsenKE JawahirS. 2012. Methicillin-resistant Staphylococcus aureus (MRSA) isolated from pets living in households with MRSA-infected children. Clin. Infect. Dis. 54:449\u2013450.","journal-title":"Clin. Infect. Dis."},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1748-5827.2011.01165.x"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01788-09"},{"key":"e_1_3_2_8_2","volume-title":"CLSI document M7-A9.","author":"Clinical and Laboratory Standards Institute","year":"2012","unstructured":"Clinical and Laboratory Standards Institute. 2012. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard, 9th ed. CLSI document M7-A9. Clinical and Laboratory Standards Institute, Wayne, PA.","edition":"9"},{"key":"e_1_3_2_9_2","volume-title":"CLSI document M45-A2.","author":"Clinical and Laboratory Standards Institute","year":"2010","unstructured":"Clinical and Laboratory Standards Institute. 2010. Methods for antimicrobial dilution and disk susceptibility testing of infrequently isolated fastidious bacteria; approved standard, 2nd ed. CLSI document M45-A2. Clinical and Laboratory Standards Institute, Wayne, PA.","edition":"2"},{"key":"e_1_3_2_10_2","unstructured":"European Committee on Antimicrobial Susceptibility Testing. 2012. Clinical breakpoints bacteria v. 2.0. Breakpoint tables for interpretation of MICs and zone diameters. European Committee on Antimicrobial Susceptibility Testing London United Kingdom. http:\/\/www.eucast.org\/clinical_breakpoints\/."},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0026978"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00330-12"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-3164.2012.01047.x"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00149-08"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0196-0644(80)80188-0"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1128\/jcm.8.6.667-672.1978"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/14.3.633"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.32.2.213"},{"key":"e_1_3_2_19_2","volume-title":"Healthcare Cost and Utilization Project Statistical Briefs.","author":"Holmquist L","year":"2010","unstructured":"HolmquistL ElixhauserA. 2010. Emergency department visits and inpatient stays involving dog bites, 2008. Statistical brief no. 101. Healthcare Cost and Utilization Project Statistical Briefs. Agency for Healthcare Policy and Research, Rockville, MD."},{"key":"e_1_3_2_20_2","unstructured":"Humane Society of the United States. 2012. American Pet Products Manufacturers Association (APPMA) 2011-2012 national pet owners survey. The Humane Society of the United States Washington DC. http:\/\/www.americanpetproducts.org\/press_industrytrends.asp."},{"key":"e_1_3_2_21_2","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1093\/jac\/dki312","article-title":"Prevalence of methicillin-resistant Staphylococcus aureus among staff and pets in a small animal referral hospital in the UK","volume":"56","author":"Loeffler A","year":"2005","unstructured":"LoefflerA. 2005. Prevalence of methicillin-resistant Staphylococcus aureus among staff and pets in a small animal referral hospital in the UK. J. Antimicrob. Chemother. 56:692\u2013697.","journal-title":"J. Antimicrob. Chemother."},{"key":"e_1_3_2_22_2","volume-title":"Manual of clinical microbiology","author":"Murray PR","year":"2007","unstructured":"MurrayPR (ed). 2007. Manual of clinical microbiology, 9th ed. ASM Press, Washington, DC.","edition":"9"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(09)70110-0"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.42.12.5881-5884.2004"},{"key":"e_1_3_2_25_2","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1136\/ip.2.1.52","article-title":"Dog bites: how big a problem?","volume":"2","author":"Sacks JJ","year":"1996","unstructured":"SacksJJ KresnowM HoustonB. 1996. Dog bites: how big a problem? Inj. Prev. 2:52\u201354.","journal-title":"Inj. Prev."},{"key":"e_1_3_2_26_2","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1093\/cid\/cir147","article-title":"Ceftaroline: a novel cephalosporin with activity against methicillin-resistant Staphylococcus aureus","volume":"52","author":"Saravolatz LD","year":"2011","unstructured":"SaravolatzLD SteinG JohnsonLB. 2011. Ceftaroline: a novel cephalosporin with activity against methicillin-resistant Staphylococcus aureus. Clin. Infect. Dis. 52:1156\u20131163.","journal-title":"Clin. Infect. Dis."},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1086\/497143"},{"key":"e_1_3_2_28_2","first-page":"85","article-title":"The bacteriology and management of dog and cat bite wound infections presenting to emergency departments","volume":"340","author":"Talan DA","year":"1999","unstructured":"TalanDA. 1999. The bacteriology and management of dog and cat bite wound infections presenting to emergency departments. N. Engl. J. Med. 340:85\u201392.","journal-title":"N. Engl. J. Med."},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1128\/jcm.27.1.78-81.1989"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.279.1.51"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01794-12","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01794-12","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T22:20:41Z","timestamp":1645482041000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.01794-12"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,12]]},"references-count":29,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2012,12]]}},"alternative-id":["10.1128\/AAC.01794-12"],"URL":"https:\/\/doi.org\/10.1128\/aac.01794-12","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,12]]},"assertion":[{"value":"2012-08-29","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2012-09-23","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2012-12-11","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}